Management of sporadic desmoid-type fibromatosis: A European consensus approach based on patients’ and professionals’ expertise – A Sarcoma Patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative

B. Kasper; C. Baumgarten; S. Bonvalot; R. Haas; F. Haller; P. Hohenberger; G. Moreau; W.T.A. van der Graaf; A. Gronchi

doi:10.1016/j.ejca.2014.11.005

journal article Jan 01, 2015

Management of sporadic desmoid-type fibromatosis: A European consensus approach based on patients’ and professionals’ expertise – A Sarcoma Patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative

B. Kasper C. Baumgarten S. Bonvalot R. Haas F. Haller P. Hohenberger G. Moreau W.T.A. van der Graaf A. Gronchi

European Journal of Cancer Vol. 51 No. 2 pp. 127-136 · Elsevier BV

View at Publisher Save 10.1016/j.ejca.2014.11.005

Topics

No keywords indexed for this article. Browse by subject →

References

40

[1]

Kasper "Desmoid tumors – clinical features and treatment options for advanced disease" Oncologist (2011) 10.1634/theoncologist.2010-0281

[2]

Wang "CTNNB1 genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm" Pediatr Dev Pathol (2012) 10.2350/11-07-1064-oa.1

[3]

Gronchi "Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasing neoplasm – position paper from the Italian and French Sarcoma Group" Ann Oncol (2014) 10.1093/annonc/mdt485

[4]

Le Guellec "CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics" Mol Pathol (2012) 10.1038/modpathol.2012.115

[5]

Lazar "Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors" Am J Pathol (2008) 10.2353/ajpath.2008.080475

[6]

Colombo "CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study" Cancer (2013) 10.1002/cncr.28271

[7]

Dômont "High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management" Br J Cancer (2010) 10.1038/sj.bjc.6605557

[8]

Mullen "β-Catenin mutation status and outcomes in sporadic desmoid tumors" Oncologist (2013) 10.1634/theoncologist.2012-0449

[9]

Castellazzi "Can the MRI signal of aggressive fibromatosis be used to predict its behaviour?" Eur J Radiol (2009) 10.1016/j.ejrad.2008.10.012

[10]

Kasper "Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib" Eur J Nucl Med Mol Imag (2010) 10.1007/s00259-010-1498-x

[11]

Dimitrakopoulou-Strauss "Dynamic PET with FDG in patients with unresectable aggressive fibromatosis: regression-based parametric images and correlation to the FDG kinetics based on a 2-tissue compartment model" Clin Nucl Med (2012) 10.1097/rlu.0b013e31825b1da4

[12]

Kasper "Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib" Biomed Res Int (2013) 10.1155/2013/389672

[13]

Trovik "Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 599 surgically-treated patients from the Scandinavian Sarcoma Group register" Eur J Cancer (2000) 10.1016/s0959-8049(99)00287-7

[14]

Stojadinovic "Analysis of the prognostic significance of microscopic margins in 2084 localized primary adult soft tissue sarcomas" Ann Surg (2002) 10.1097/00000658-200203000-00015

[15]

Prognostic factors for patients with localized soft‐tissue sarcoma treated with conservation surgery and radiation therapy

Gunar K. Zagars, Matthew T. Ballo, Peter W. T. Pisters et al.

Cancer 2003 10.1002/cncr.11365

[16]

Gronchi "Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival" Ann Surg (2010) 10.1097/sla.0b013e3181cf87fa

[17]

Gronchi "Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: A series of patients surgically treated at a single institution" J Clin Oncol (2003) 10.1200/jco.2003.05.150

[18]

Lev "Optimizing treatment of desmoid tumors" J Clin Oncol (2007) 10.1200/jco.2006.10.5015

[19]

Salas "Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation" J Clin Oncol (2011) 10.1200/jco.2010.33.5489

[20]

Bonvalot "Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients" Eur J Surg Oncol (2008) 10.1016/j.ejso.2007.06.006

[21]

Lewis "The enigma of desmoid tumors" Ann Surg (1999) 10.1097/00000658-199906000-00014

[22]

Fiore "Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment" Ann Surg Oncol (2009) 10.1245/s10434-009-0586-2

[23]

Briand "Wait-and-See policy as a first-line management for extra-abdominal desmoid tumors" J Bone Joint Surg Am (2014) 10.2106/jbjs.m.00988

[24]

Bonvalot "Spontaneous regression of primary abdominal wall desmoids: more common than previously thought" Ann Surg Oncol (2013) 10.1245/s10434-013-3197-x

[25]

Bonvalot "Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1mg and melphalan (T1-M HILP) is safe and efficient" Ann Surg Oncol (2009) 10.1245/s10434-009-0733-9

[26]

Kujak "Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors" Skeletal Radiol (2010) 10.1007/s00256-009-0801-z

[27]

<http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf> version, 1; 2013.

[28]

"Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" Ann Oncol (2014)

[29]

Guadagnolo "Long-term outcomes for desmoid tumors treated with radiation therapy" Int J Radiat Oncol Biol Phys (2008) 10.1016/j.ijrobp.2007.10.013

[30]

Keus "Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis – an EORTC STBSG and ROG study (EORTC 62991–22998)" Ann Oncol (2013) 10.1093/annonc/mdt254

[31]

Janinis "The pharmacological treatment of aggressive fibromatosis: a systematic review" Ann Oncol (2003) 10.1093/annonc/mdg064

[32]

Skapek "Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a children’s oncology group (COG) phase II study" Pediatr Blood Cancer (2013) 10.1002/pbc.24457

[33]

Skapek "Vinblastine and methotrexate for desmoid fibromatosis in children: results of a pediatric oncology group phase II trial" J Clin Oncol (2007) 10.1200/jco.2006.08.2966

[34]

Garbay "Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG)" Ann Oncol (2012) 10.1093/annonc/mdr051

[35]

Constantinidou "Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis" Eur J Cancer (2009) 10.1016/j.ejca.2009.08.016

[36]

Heinrich "Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumour)" J Clin Oncol (2006) 10.1200/jco.2005.04.0717

[37]

Penel "Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up" Ann Oncol (2011) 10.1093/annonc/mdq341

[38]

Kasper Ann Oncol (2014) 10.1093/annonc/mdu354.1

[39]

Gounder "Activity of sorafenib against desmoid tumor/deep fibromatosis" Clin Cancer Res (2011) 10.1158/1078-0432.ccr-10-3322

[40]

Fiore "Desmoid-type fibromatosis and pregnancy" Ann Surg (2014) 10.1097/sla.0000000000000224

Metrics

190

Citations

40

References

Details

Published: Jan 01, 2015
Vol/Issue: 51(2)
Pages: 127-136
License: View

Authors

Cite This Article

B. Kasper, C. Baumgarten, S. Bonvalot, et al. (2015). Management of sporadic desmoid-type fibromatosis: A European consensus approach based on patients’ and professionals’ expertise – A Sarcoma Patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. European Journal of Cancer, 51(2), 127-136. https://doi.org/10.1016/j.ejca.2014.11.005

Management of sporadic desmoid-type fibromatosis: A European consensus approach based on patients’ and professionals’ expertise – A Sarcoma Patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative

You May Also Like